GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Operating Margin %

AN2 Therapeutics (AN2 Therapeutics) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. AN2 Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-18.30 Mil. AN2 Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, AN2 Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for AN2 Therapeutics's Operating Margin % or its related term are showing as below:


ANTX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.555
* Ranked among companies with meaningful Operating Margin % only.

AN2 Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

AN2 Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-18.30 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-71.89 Mil.


AN2 Therapeutics Operating Margin % Historical Data

The historical data trend for AN2 Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AN2 Therapeutics Operating Margin % Chart

AN2 Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Operating Margin %
- - - -

AN2 Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AN2 Therapeutics's Operating Margin %

For the Biotechnology subindustry, AN2 Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AN2 Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where AN2 Therapeutics's Operating Margin % falls into.



AN2 Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

AN2 Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-69.635 / 0
= %

AN2 Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-18.296 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AN2 Therapeutics  (NAS:ANTX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


AN2 Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of AN2 Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AN2 Therapeutics (AN2 Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Executives
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Kabeer Aziz director 376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Adjuvant Global Health Technology Fund De, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Robin Shane Readnour director 3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Kevin Michael Krause officer: Chief Strategy Officer 369 27TH STREET, SAN FRANCISCO CA 94131
Eric Easom director, officer: Chief Executive Officer 171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Joshua M Eizen officer: See Remarks 3023 MONTBRETIA WAY, SAN RAMON CA 94582
Margaret M Fitzpatrick director C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Ra Capital Nexus Fund Ii, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Melvin K Spigelman director THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Sanjay Chanda officer: Chief Development Officer C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Adjuvant Global Health Technology Fund, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak officer: Chief Accounting Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Lucy Day officer: Chief Financial Officer 2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301